Background Glucocorticoid Therapy Has No Impact on Efficacy and Safety of Abatacept or Adalimumab in Patients with Rheumatoid Arthritis

Documenti analoghi

• Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE)
  di: Fleischmann, Roy, et al.
  Pubblicazione: (2019)
• Patient‐Reported Outcomes From a Two‐Year Head‐to‐Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis
  di: Fleischmann, Roy, et al.
  Pubblicazione: (2016)
• Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
  di: Weinblatt, Michael E, et al.
  Pubblicazione: (2013)
• Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
  di: Schiff, Michael, et al.
  Pubblicazione: (2014)
• Brief Report: Estimating Disease Activity Using Multi‐Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab
  di: Fleischmann, Roy, et al.
  Pubblicazione: (2016)